Controversies in varicella: Vaccine and acyclovir

Current Opinion in Infectious Diseases

Volumn 9, Issue 3, 1996, Pages 203-209

  Kennedy, Nick ^a   McKendrick, Michael W ^b  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CHICKENPOX VACCINE;

CHICKENPOX; CLINICAL FEATURE; DRUG EFFICACY; FEVER; HEALTH CARE COST; HERPES ZOSTER; HUMAN; IMMUNE DEFICIENCY; IMMUNOGENICITY; INJECTION PAIN; NEWBORN DISEASE; PNEUMONIA; PROPHYLAXIS; RASH; REVIEW; THORAX RADIOGRAPHY;

EID: 0030016127     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199606000-00013     Document Type: Review

References (61)

1. Committee on Infectious Diseases of the American Academy of Pediatrics: Recommendations for the use of live attenuated varicella vaccine. Pediatrics 1995, 95:791-796. As well as giving the recommendations of the American Academy of Pediatrics for vaccine use (universal use in early childhood and immunization in susceptible older children and adolescents is recommended), this article reviews the data on which these recommendations are based in some detail.
2. Choo PW, Donahue JG, Manson JE, Platt R: The epidemiology of varicella and its complications. J Infect Dis 1995, 172:706-712. The records of over 250 000 members of a health maintenance programme in New England were analysed to assess the epidemiology of varicella and its complications. The main findings were that incidence rates of varicella in persons under 15 years of age were 20-50% lower than the published figures (probably as a result of under-reporting), whereas rates in individuals of 15 years or older were greater than predicted. The rates of hospitalization for complicated and uncomplicated varicella were many times higher than expected from earlier studies.
3. Finger R, Hughes JP, Meade BJ, Pelletier AR, Palmer CT: Age-specific incidence of chickenpox. Public Health Rep 1994, 109:750-755.
4. Guess HA, Broughton DD, Melton LJ III, Kurland LT: Population-based studies of varicella complications. Pediatrics 1986, 78(suppl):723-727.
5. Newey ML, Magnussen PA: Deep hand infection complicating chickenpox in an otherwise healthy infant [Case report]. Br J Clin Pract 1995, 49:53.
6. Wilson GJ, Talkington DF, Gruber W, Edwards K, Dermody TS: Group A streptococcal necrotizing fasciitis following varicella in children: case reports and review. Clin Infect Dis 1995, 20:1333-1338. Four cases of necrotizing fasciitis are reported, which were associated with group A β-haemolytic Streptococcus infection after varicella in children aged 2-8 years and that occurred in one hospital in Nashville, Tennessee during the period 1991-1993. Eleven other cases reported in the English-language literature since 1970 are reviewed.
7. Brogan TV, Nizet V, Waldhausen JHT, Rubens CE, Clarke WR: Group A streptococcal necrotizing fasciitis complicating primary varicella: a series of fourteen patients. Pediatr Infect Dis J 1995, 14:588-594. Fourteen children aged 6 months to 10 years with group A β-haemolytic Streptococcus necrotizing fasciitis after varicella were admitted to one hospital in Seattle, USA, over an 18-month period. The virulence factors of invasive group A Streptococcus, clinical presentation, diagnosis and management are discussed.
8. González-Ruiz A, Ridgway GL, Cohen SL, Hunt CP, McGrouther G, Adiseshiah M: Varicella gangrenosa with toxic shock-like syndrome due to group A streptococcus infection in an adult: case report. Clin Infect Dis 1995, 20:1058-1060. A further case of necrotizing fasciitis, this time in an adult patient, is reported. An editorial response by D.L. Stevens accompanies the article in the same issue (pp. 1061-1062).
9. Nguyén P, Reynaud J, Pouzol P, Munzer M, Richard O, François P: Varicella and thrombotic complications associated with transient protein C and protein S deficiencies in children. Eur J Pediatr 1994, 153:646-649.
10. Tsolia M, Skardoutsou A, Tsolas G, Karayanni C, Spyridis P, Sinaniotis C: Pre-eruptive neurologic manifestations associated with multiple cerebral infarcts in varicella. Pediatr Neurol 1995, 12:165-168.
11. Amlie-Lefond C, Kleinschmidt-DeMasters BK, Mahalingam R, Davis LE, Gilden DH: The vasculopathy of varicella-zoster virus encephalitis. Ann Neurol 1995, 37:784-790.
12. Pratt RD, Bradley JS, Loubert C, LaRocco A Jr, McNeal RM, Newbury RO, Sawyer MH: Rhabdomyolysis associated with acute varicella infection. Clin Infect Dis 1995, 20:450-453.
13. Liu HC, Tsai TC, Chang PY, Shih BF: Varicella orchitis: report of two cases and review of the literature. Pediatr Infect Dis J 1994, 13:748-750.
14. Rice P, Simmons K, Carr R, Banatvala J: Near fatal chickenpox during prednisolone treatment. BMJ 1994, 309:1069-1070. A case of disseminated varicella in an adult patient receiving prednisolone therapy for idiopathic thrombocytopenia is presented and discussed. The paper provoked considerable subsequent correspondence regarding varicella in patients receiving systemic corticosteroids.
15. Committee on Safety of Medicines and the Medicines Control Agency: Severe chickenpox associated with systemic corticosteroids. Curr Probl Pharmacovig 1994, 20:1-2.
16. Deutsch DE, Olson AD, Kraker S, Dickinson CJ: Overwhelming varicella pneumonia in a patient with Crohn's disease treated with 6-mercaptopurine. J Pediatr Gastroenterol Nutr 1995, 20:351-353.
17. Gatnash AA, Connolly CK: Fatal chickenpox pneumonia in an asthmatic patient on oral steroids and methotrexate. Thorax 1995, 50:422-423.
18. Choong K, Zwaigenbaum L, Onyett H: Severe varicella after low dose inhaled corticosteroids. Pediatr Infect Dis J 1995, 14:809-810.
19. Zambrano MA, Martinez A, Minguez JA, Vázquez F, Palencia R: Varicella pneumonia complicating pregnancy. Acta Obstet Gynecol Scand 1995, 74:318-320.
20. Ghidini A, Lynch L: Management strategies for congenital infections. Mt Sinai J Med 1994, 61:376-388.
21. Prober CG, Gershon MD, Grose C, McCracken GH, Nelson JD: Consensus: varicella-zoster infections in pregnancy and the perinatal period. Pediatr Infect Dis J 1990, 9:865-869.
22. Rowland P, Wald ER, Mirro JR Jr, Yunis E, Albo VC, Wollman MR, Blatt J: Progressive varicella presenting with pain and minimal skin involvement in children with acute lymphoblastic leukemia. J Clin Oncol 1995, 13:1697-1703. The experience at the Children's Hospital of Pittsburgh of 42 cases of VZV infection in 294 children with acute lymphoblastic leukemia is reviewed. The clinical presentation of patients with progressive varicella was dominated by abdominal and back pain rather than skin involvement. Disappointingly, significant morbidity and mortality was observed in patients who had received acyclovir (and VZIG), although delayed diagnoses as a result of atypical presentation may have contributed to the poor outcome.
23. Ozaki T, Kajita Y, Asano Y, Aono T, Yamanishi K: Detection of varicella-zoster virus DNA in blood of children with varicella. J Med Virol 1994, 44:263-265. A nested polymerase chain reaction method was used to detect VZV DNA in peripheral blood mononuclear cells from children with varicella. The rate of PCR detection was highest (67%) between 5 and 1 day before the onset of the rash, declining to zero 15 days after the onset of the rash.
24. Nahass GT, Mandel MJ, Cook S, Fan W, Leonardi CL: Detection of herpes simplex and varicella-zoster infection from cutaneous lesions in different clinical stages with the polymerase chain reaction. J Am Acad Dermatol 1995, 32:730-733. Polymerase chain reaction was able to detect VZV and HSV DNA reliably in stained Tzanck smears, vesicle fluid swabs, dried crusts and skin biopsy specimens.
25. McKendrick MW: Acyclovir for childhood chickenpox. Cost is unjustified. BMJ 1995, 310:108-109. In this review article the use of acyclovir therapy for otherwise healthy children with varicella is discussed. It is concluded that routine use is not justified.
26. Balfour HH Jr: Acyclovir for childhood chickenpox. No reason not to treat. BMJ 1995, 310:109-110. The safety of acyclovir and its ability to shorten the course of varicella by 25-33% and reduce the 'misery index' are the main arguments given for acyclovir use in healthy children in this review.
27. Balfour HH Jr, Kelly JM, Suarez CS, Heussner RC, Englund JA, Crane DD, McGuirt PV, Clemmer AF, Aeppli DM: Acyclovir treatment of varicella in otherwise healthy children. J Pediatr 1990, 116.633-639.
28. Dunkle LM, Arvin AM, Whitley RJ, Rotbart HA, Feder HM, Feldman S, Gershon AA, Levy ML, Hayden GF, McGuirt PV et al.: A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med 1991, 325:1539-1544.
29. Morrison Y: Varicella-zoster virus: recent therapeutic advances. J Pediatr Health Care 1995, 9:81-86.
30. Balfour HH, Rotbart HA, Feldman S, Dunkle LM, Feder HM, Prober CG, Hayden GF, Steinberg S, Whitley RJ, Goldberg L et al. and the Collaborative Acyclovir Varicella Study Group: Acyclovir treatment of varicella in otherwise healthy adolescents. J Pediatr 1992, 120:627-633.
31. Chiodo F, Manfredi R, Antonelli P, Caramia G, Carnelli V, Catania S, Ceccarelli M, De Santis U, Ghirardini G, Loizzo B et al. and the Italian Acyclovir-Chickenpox Study Group: Varicella in immunocompetent children in the first two years of life: role of treatment with oral acyclovir. J Chemother 1995, 7:62-66. An open multicentre study of 53 immunocompetent children aged 3-24 months, who received oral acyclovir therapy either in the first 24 h or within 48 h of the onset of rash. No significant difference in outcome was observed for the two groups. Although of interest as one of the few recent studies of acyclovir therapy in normal children, the study is severely compromised by its small sample size, open design and lack of placebo group.
32. Levin MJ, Rotbart HA, Hayward AR: Immune response to varicella-zoster virus 5 years after acyclovir therapy of childhood varicella. J Infect Dis 1995, 171:1383-1384.
33. Committee on Infectious Diseases of the American Academy of Pediatrics: The use of oral acyclovir in otherwise healthy children with varicella. Pediatrics 1993, 91:674-676.
34. Prober CG, Kirk LE, Keeney RE: Acyclovir therapy of chickenpox in immunosuppressed children - a collaborative study. J Pediatr 1982, 101:622-625.
35. McKendrick MW, McGill JI, Wood MJ: Lack of effect of acyclovir on post-herpetic neuralgia [Letter]. BMJ 1989, 298:431.
36. Huff JC, Drucker JL, Clemmer A, Laskin OL, Connor JD, Bryson YJ, Balfour HH Jr: Effect of oral acyclovir on pain resolution in herpes zoster: a reanalysis. J Med Virol 1993, 4(suppl 1):93-96.
37. British Society for the Study of Infection: Guidelines for the management of singles. J Infect 1995, 30:193-200. This report sets out guidelines for the management of shingles in immunocompetent and immunocompromised patients, ophthalmic zoster and post-herpetic neuralgia. Infection control measures are also discussed, and priorities for future research are identified.
38. Takaue Y, Okamoto Y, Kawano Y, Suzue T, Abe T, Saito SI, Sato J, Hirao A, Makimoto A, Kawahito M et al.: Regeneration of immunity and varicella-zoster virus infection after high-dose chemotherapy and peripheral blood stem cell autografts in children. Bone Marrow Transplant 1994, 14:219-223.
39. Poscher ME: Successful treatment of varicella zoster virus meningoencephalitis in patients with AIDS: report of four cases and review. AIDS 1994, 8:1115-1117.
40. Huang YC, Lin TY, Chiu CH: Acyclovir prophylaxis of varicella after household exposure. Pediatr Infect Dis J 1995, 14:152-154.
41. White CB, Hawley WZ, Harford DJ: The pediatric resident susceptible to varicella: providing immunity through postexposure prophylaxis with oral acyclovir. Pediatr Infect Dis J 1994, 13:743-745.
42. Ellender D, Waller P, Wood S, Rawlins M, Langman M, Salisbury D, Wilson E: Severe chickenpox during treatment with corticosteroids. National guidelines exist [Letter]. BMJ 1995, 310.327.
43. Easterbrook P, Wood MJ: Successors to acyclovir. J Antimicrob Chemother 1994, 34:307-311.
44. Tyring S, Barbarash RA, Nahlik JE, Cunningham A, Marley J, Heng M, Jones T, Rea T, Boon R, Saltzman R and the Collaborative Famciclovir Herpes Zoster Study Group: Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995, 123:89-96. In this randomized, double-blind multicentre study 419 immunocompetent adult patients with zoster received either famciclovir or placebo for 7 days. Famciclovir was well tolerated, accelerated lesion healing, reduced the duration of acute viral shedding and reduced the duration of post-herpetic neuralgia (defined as pain after skin healing) compared with placebo.
45. Beutner KR, Friedman DJ, Forszpaniak C, Anderson PL, Wood MJ: Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995, 39:1546-1553. This large (>1100 adult patients) randomized, double-blind multicentre study compared oral acyclovir 800 mg five times a day for 7 days with valaciclovir 1000 mg three times a day for 7 or 14 days. Valaciclovir taken for 7 or 14 days significantly accelerated the resolution of zoster-associated pain and reduced the duration of post-herpetic neuralgia compared to patients receiving acyclovir. There were no significant differences between the groups in adverse events.
46. Machida H, Nishitani M, Watanabe Y, Yoshimura Y, Kano F, Sakata S: Comparison of the selectivity of anti-varicella-zoster virus nucleoside analogues. Microbiol Immun 1995, 39:201-206.
47. Peck RW, Weatherley BC, Wootton R, Crome P, Holdich TA, Posner J: Pharmacokinetics and tolerability of single oral doses of 882C87, a potent, new anti-varicella-zoster virus agent, in healthy volunteers. Antimicrob Agents Chemother 1995, 39:20-27.
48. Marwick C: Lengthy tale of varicella vaccine development finally nears a clinically useful conclusion. JAMA 1995, 273:833-834, 836.
49. Gershon AA: Varicella vaccine: its past, present and future. Pediatr Infect Dis J 1995, 14:742-744.
50. Watson B, Boardman C, Laufer D, Piercy S, Tustin N, Olaleye D, Cnaan A, Starr SE: Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clin Infect Dis 1995, 20:316-319. The cell-mediated and humoral immune responses of 200 healthy children were compared to one or two doses of live attenuated varicella vaccine. Both cell-mediated immunity and humoral responses were significantly stronger at 1 year in children who had received two vaccine doses 3 months apart. Further studies of the clinical benefit of two rather than one dose of vaccine in children are recommended.
51. Clements DA, Armstrong CB, Ursano AM, Moggio MM, Walter EB, Wilfert CM: Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents. Pediatr Infect Dis J 1995, 14:874-879. This is a follow-up study of 465 healthy children and adolescents (age range 12 months to 17 years) vaccinated with the live attenuated varicella vaccine between 1984 and 1989. The overall seroconversion rate was 94.6%, but varied from 85 to 100% according to the plaque-forming units in the vaccine production lot. Break-through disease occurred in 18.6% of seroconverters during follow-up, but was generally mild. An inverse relationship was seen between the development of break-through varicella and the titre of antibodies to VZV 6 weeks post vaccination.
52. Nader S, Bergen R, Sharp M, Arvin AM: Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. J Infect Dis 1995, 171:13-17. This study looks at cell-mediated immunity to VZV induced by one or two doses of vaccine in adults and children. The results confirm that the cell-mediated immunity response is diminished in adult vaccinees compared to children. Cell-mediated immunity responses at 1 year were significantly higher in children receiving two rather than one dose of vaccine.
53. Watson B, Rothstein E, Bernstein H, Arbeter A, Arvin A, Chartrand S, Clements D, Kumar ML, Reisinger K, Blatter M et al.: Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. J Infect Dis 1995, 172:217-219. Humoral immune response and VZV-specific lymphoproliferation response to a booster dose of vaccine was assessed in 419 children and adolescents vaccinated with live attenuated varicella vaccine 4-6 years earlier. Of the 419 children, 414 (99%) had remained seropositive after the initial vaccination. The booster dose was well tolerated and effective at boosting antibody titres and lymphocyte proliferation responses.
54. Kutler BJ, Weibel RE, Guess HA, Matthews H, Morton DH, Neff BJ, Provost PJ, Watson BA, Starr SE, Plotkin SA: Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy and 7-year follow-up studies. Vaccine 1991, 9:643-647.
55. Gershon AA: Varicella-zoster virus: prospects for control. Adv Pediatr Infect Dis 1995, 10:93-124. This is an excellent and comprehensive review which covers most aspects of VZV infection. Some interesting follow-up data is included regarding the use of the live attenuated varicella vaccine in immunocompromised children.
56. Ferson MJ: Another vaccine, another treadmill? J Paediatr Child Health 1995, 31:3-5. This review discusses the possible disadvantages as well as the advantages of universal vaccination in infancy, and concludes that universal vaccination cannot be advocated at present.
57. Ross LF, Lantos JD: Immunisation against chickenpox. BMJ 1995, 310:2-3. After discussing the pros and cons of vaccination, this editorial also concludes that a policy of universal vaccination is not justified. Restricting immunization to high-risk children is advocated.
58. Halloran ME, Cochi SL, Lieu TA, Wharton M, Fehrs L: Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol 1994, 140:81-104.
59. Lieu TA, Cochi SL, Black SB, Halloran ME, Shinefield HR, Holmes SJ, Wharton M, Washington AE: Cost-effectiveness of a routine varicella vaccination programme for US children. JAMA 1994, 271:375-381.
60. Lieu TA, Finkler LJ, Sorel ME, Black SB, Shinefield HR: Cost-effectiveness of varicella serotesting versus presumptive vaccination of school-age children and adolescents. Pediatrics 1995, 95:632-638. A decision analysis model was constructed on the basis of published and unpublished data to evaluate the cost-effectiveness of presumptive vaccination versus serological testing of school-age children and adolescents with a negative or uncertain history of varicella. Presumptive vaccination was found to be a relatively cost-effective policy for school-age children, but not for adolescents.
61. Skinner GR, Davies J: Immunisation against chickenpox. Good argument exists for universal vaccination [Letter]. BMJ 1995, 310:873.